These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 29703539

  • 21. Identification of a novel ALK inhibitor-sensitive PRKCE-ALK gene fusion in lung adenocarcinoma.
    Wang L, Li L, Zhou X, Zhang D.
    Lung Cancer; 2024 May; 191():107797. PubMed ID: 38669726
    [No Abstract] [Full Text] [Related]

  • 22. Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer.
    Shiihara J, Ohyanagi F, Amari H, Toda M, Tahara H, Yuzawa M, Maeda Y, Nomura M, Mizushina Y, Nagai Y, Ohta H, Yamaguchi Y.
    Thorac Cancer; 2021 Sep; 12(17):2420-2423. PubMed ID: 34324792
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. A novel intergenic region (chr2: 30,193,816)-ALK fusion shows sensitivity to Alectinib in lung adenocarcinoma.
    Wang T, Du G, Niu M, Liu R.
    BMC Pulm Med; 2023 Feb 08; 23(1):60. PubMed ID: 36755262
    [Abstract] [Full Text] [Related]

  • 27. Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma.
    Koyama K, Katsurada N, Jimbo N, Tachihara M, Tamura D, Nakata K, Nagano T, Yamamoto M, Kamiryo H, Kobayashi K, Itoh T, Nishimura Y.
    Pathol Int; 2019 May 08; 69(5):294-299. PubMed ID: 30900377
    [Abstract] [Full Text] [Related]

  • 28. SMPD3-ALK: A novel ALK fusion gene in lung adenocarcinoma.
    Liang Y, Wang Y, Wang W, Zhao J, Xu M, Zheng M.
    Clin Genet; 2021 Mar 08; 99(3):488-489. PubMed ID: 33556194
    [Abstract] [Full Text] [Related]

  • 29. Response of a Novel KANK1::ALK Fusion to Alectinib in an Advanced Lung Adenocarcinoma: A Case Report.
    Tang Q, Li T, Ren F, Li X, Cao W, Yu H, Mao F, Cao C, Zu L, Xu S.
    J Natl Compr Canc Netw; 2024 Feb 15; 22(2):. PubMed ID: 38364363
    [Abstract] [Full Text] [Related]

  • 30. Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review.
    Wang Z, Wu R, Li C, Cheng K, Di Y, Lv T, Liu H, Song Y.
    Anticancer Drugs; 2023 Nov 01; 34(10):1069-1075. PubMed ID: 36688904
    [Abstract] [Full Text] [Related]

  • 31. Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation.
    Baglivo S, Ricciuti B, Ludovini V, Metro G, Siggillino A, De Giglio A, Chiari R.
    J Thorac Oncol; 2018 Aug 01; 13(8):e145-e147. PubMed ID: 30049377
    [No Abstract] [Full Text] [Related]

  • 32. Identification of a novel LRRC4C-ALK fusion in lung adenocarcinoma and outcome of the response to anaplastic lymphoma kinase inhibitors.
    Wang H, Li Z, Qi X, Wang W, Lin Y.
    J Gene Med; 2021 Mar 01; 23(3):e3316. PubMed ID: 33559138
    [No Abstract] [Full Text] [Related]

  • 33. Chr2 30297612-ALK, A Novel Intergenic Fusion With Exon18 of ALK, Responds to Crizotinib.
    Chen X, Zhao G, Zhong P, Zhang M, Chen R, Zhang D.
    Clin Lung Cancer; 2020 Nov 01; 21(6):e564-e566. PubMed ID: 32576444
    [No Abstract] [Full Text] [Related]

  • 34. A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib.
    Lim CA, Banyi N, Tucker T, Ionescu DN, Melosky B.
    Curr Oncol; 2022 Feb 03; 29(2):848-852. PubMed ID: 35200571
    [Abstract] [Full Text] [Related]

  • 35. Safety and Efficacy of Alectinib in a Patient With Advanced NSCLC Undergoing Hemodialysis.
    Suzuki S, Haratani K, Takahama T, Watanabe S, Takegawa N, Hayashi H, Takeda M, Yonesaka K, Nakagawa K.
    J Thorac Oncol; 2019 Mar 03; 14(3):e50-e52. PubMed ID: 30782383
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report.
    Shirasawa M, Kubotaa M, Harada S, Niwa H, Kusuhara S, Kasajima M, Hiyoshi Y, Ishihara M, Igawa S, Masuda N.
    Lung Cancer; 2016 Sep 03; 99():66-8. PubMed ID: 27565916
    [Abstract] [Full Text] [Related]

  • 39. MPRIP-ALK, a Novel ALK Rearrangement That Responds to ALK Inhibition in NSCLC.
    Fang W, Gan J, Hong S, Lu F, Zhang L.
    J Thorac Oncol; 2019 Jul 03; 14(7):e148-e151. PubMed ID: 31235041
    [No Abstract] [Full Text] [Related]

  • 40. Alectinib-responsive infantile anaplastic ganglioglioma with a novel VCL-ALK gene fusion.
    Yamamoto S, Koga Y, Ono H, Goto H, Hata N, Yamamoto H, Suzuki SO, Sakai Y, Iwaki T, Ohga S.
    Pediatr Blood Cancer; 2021 Sep 03; 68(9):e29122. PubMed ID: 34019333
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.